This in fact an issue policy of first order

Each of us is, or will necessarily face taking medications, for treating mild headache but also for "life". Progress of life in the past in our developed countries half-century is now fifteen years and no one can deny the decisive contribution of the drug to this progress. In this context, it is paradoxical to celebrate the decay of the consumption of the drug, while new diseases appear and that of many diseases have still only very partial therapeutic responses!

The drug industry know that represents progress getting investment, hazards, risks and procedures. They know the economic issue of these innovations in a world more complex and unpredictable. They can enjoy as a result the scope of this decay, completely new in France, and they were permitted by signing agreements to economies with public authorities. It was where our share neither schizophrenia nor candor, but an approach of responsibility to contribute to the preservation of a solidarity-based health system that is the honour of our country.

There is indeed a double dimension of the drug, welfare to which each must be able to access the permanent search of fragile economic balances and much economic, high-technology companies. This in fact an issue policy of first order. Unfortunately, the debate on the drug it is enclosed since the 1990s in reducing its cost for the company field. He became the subject of a stigma on the ground, said, overuse, and misuse, sometimes while it is a chance for life, a wealth for the country, an economic opportunity for the nation, and a source of prosperity for the State.

Is this relevant to celebrate the decay of the drug, while its share in the expenses of health insurance should we talk about an expense or an investment represents less than 20, and 6 billion euros in non-productive health, identified savings can be realized in the system Is it our interest we should welcome a situation severely weakens an economic sector that led the France to be one of the major five countries to rely in the pharmaceutical industry of the future This year, our industry has a historic deceleration of expenditure, with a turnover growth of 1 and a level of taxation exceeding 5, more than doubled since 2002. The phenomenon is combined with an international environment which guarantees over the intellectual property, a condition sine qua non for investment. Thus, even if it continues to be the locomotive of the R & D, pharmacy sees investment decline, social plans to multiply and the balance of job creation has been divided by 3 in a few years!

In the 1990s, conventional agreements we had allowed closer the more modern regimes in Europe. But the implementation of the reform of 2004, to which the industry has provided support expensive more than 10 of its turnover in savings raises issues such as the consistency of the new governance and management of the supply of care directly by Medicare. The drug industry recognize that efforts are inadequate to identify the resources expected for the support of innovation for its fair price. They have the feeling that the decision-makers are converted to a Malthusian approach of the drug and that they do pass the industrial problems of the sector after many other arbitrations. A burst is necessary to think the context of 2010, which is at stake, our ability to use and to invent in the France medicine.

At the time where will to discuss the next project of financing of the Social Security Act, no new measures should weaken further the sector. The provisional nature of the measures passed must be respected. The State and the authorities have precisely responsible industrialists who do not want the France to spoil his chances in a field as "vital".